A comparison of outcomes among hospital survivors with and without severe comorbidity admitted to the intensive care unit 
Summary
Little is known about the experiences of patients with severe comorbidity discharged from Intensive Care Units (ICUs). This project aimed to determine the effects of an ICU stay for patients with severe comorbidity by comparing 1) quality of life (QOL), 2) the symptom profile of hospital survivors and 3) health service use after hospital discharge for patients admitted to ICU with and without severe comorbidity. A case-control study was used. Patients with severe comorbidity were matched to a contemporaneous cohort of ICU patients by age and severity of illness. Assessment tools were the Medical Outcome Study 36-item short-form and European Organisation for Research and Treatment of Cancer QLQ-C15-PAL questionnaires for QOL and the Symptom Assessment Scale for symptom distress. A proportional odds assumption was performed using an ordinal regression model. The difference in QOL outcome was the dependent variable for each pair. Health service use after discharge from ICU was monitored with patient diaries. Patients aged 18+ years admitted to an ICU in a metropolitan teaching hospital between 2011 and 2012 were included. We recruited 30 cases and 30 controls. QOL improved over the six months after hospital discharge for patients with and without severe comorbidity (P <0.01) within the groups but there was no difference found between the groups (P >0.3). There was no difference in symptoms or health service use between patients with and without severe comorbidity. ICU admission for people with severe comorbidity can be appropriate to stabilise the patient's condition and is likely to be followed by some overall improvement over the six months after hospital discharge.
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Palliative care is a holistic approach to improve quality of life (QOL) for patients who face life-threatening illness (and their families) by preventing and treating pain and other physical, psychosocial and spiritual problems 1 . It uses an interdisciplinary approach to support patients to live as actively as possible and, as such, palliative care is not restricted to care in the last days or weeks of life. Intensive care, often seen as being at the other end of the healthcare spectrum, with technology-driven, high-cost interventions and patient care, treats patients with potentially reversible life-threatening conditions with the immediate aim to save lives. Patients admitted to the intensive care unit (ICU) usually receive interventions aimed at supporting organ function to give them time to recover from critical illness. However, there is increasing intersect between palliative care and ICU, with patients with severe comorbidity regularly being admitted to ICUs for stabilisation and patients in the ICU being diagnosed as close to the end of life and requiring supportive care on discharge. The admission of patients with irreversible or severe comorbidity to ICU for either an unrelated acute illness or exacerbation of the disease itself can be considered controversial and warrants further exploration.
Although palliative care and critical care seem discordant, both intensive care and palliative care professionals manage patients with life-threatening conditions, often with multiple organ system failure, and share important similarities in clinical goals, particularly symptom management and QOL 2 . There is a group of patients who are admitted to the ICU who have severe comorbidity and who survive their episode of critical illness, but who will not fully recover from their underlying illness and, as such, may benefit from palliative care. Reports describe ICU mortality [3] [4] [5] and longer-term 6-10 mortality among patients with severe comorbidity but there are few reports describing QOL and symptom burden for these patients who survive their critical illness and are discharged into the community with a continuing life-threatening illness 11, 12 . Furthermore, there is little direction for clinicians as to when it may be appropriate to involve palliative care teams in the care of patients in ICU.
The aims of this study were firstly, to describe: 1) QOL, 2) symptom profile and 3) health service use of patients with severe comorbidity discharged from hospital after an admission to the ICU and secondly, to compare these outcomes with a group of patients with no severe comorbidity. Understanding the QOL, health service use and symptom profile of patients with severe comorbidity discharged from hospital after an admission to ICU is important in supporting patients and their families in provision of palliative care to enable patients to better manage their severe comorbidity. The comparison of outcomes of this group with other survivors of critical illness requiring ICU admission may provide much-needed information on the effect of an ICU admission on patients with severe comorbidity and the need for palliative care follow-up after discharge.
Methods

Design
Approval was obtained from the relevant Head of Department (a co-author of this paper) and Human Research Ethics Committee (Royal Perth Hospital Ethics Committee, EC 2010/126). This case-control study compared outcomes for patients admitted to the ICU who had severe comorbidity to a convenience sample of ICU patients without severe comorbidity. Severe comorbidity in this study was defined using the Chronic Health Evaluation component of the Acute Physiology and Chronic Health Evaluation (APACHE) II score, a severity of illness score routinely used in the ICU 13 . The score includes acute physiological values, chronic health evaluation points, age points and elective surgical status to compute a composite score with a maximum value of 72. The worst APACHE score in the first 24 hours of ICU admission was used. The Chronic Health Evaluation defines five severe comorbidities: cardiac (New York Heart Association classification IV), respiratory (chronic obstructive, restrictive, vascular disease resulting in severe exercise limitation, chronic hypoxia, chronic hypercapnia), renal (chronic peritoneal or haemodialysis), liver (proven cirrhosis and documented portal hypertension, prior hepatic failure/encephalopathy/coma) and immunesuppression conditions or treatment severe enough to suppress infection (e.g. leukaemia, lymphoma, acquired immune deficiency syndrome, diffuse metastatic cancer). Patients were followed from the time they were discharged from the study hospital for six months or until their death if this occurred before six months.
Participants and setting
Patients aged 18 years and older who were admitted to the 22-bed general, level III ICU 14 at a metropolitan tertiary referral hospital in Western Australia were eligible for selection. No formal sample size calculation was performed. We aimed to recruit 50 patients with severe comorbidity and 50 patients without severe comorbidity as the comparison group. Patients were recruited by the ICU clinical nurse specialists (senior nurses in the ICU) over 15 months in 2011 to 2012.
Data collection tools
Three tools were used to assess QOL and symptoms after treatment in the ICU:
Health-related QOL was estimated from the Australian (English) Medical Outcome Study 36-item short-form (SF-36v2 TM ) 15 . The SF-36v2 has two domains composed of several sub-domains: 'Physical Health on Role (Role-Physical), Bodily Pain, General Health, Vitality, Social Functioning, effect of Emotional Health on Role (Role-Emotional) and Mental Health 16 . It has been adapted for use in Australia and the release of the refined version, SF-36v2, is reported to have improved reliability and better precision 17, 18 . Scores are rated on a 100-point scale.
The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C15-PAL 19 is a palliative care-specific QOL tool. The standardised 15-item questionnaire includes questions on frequent symptoms, emotional and physical functioning and overall QOL 19, 20 .
The Symptom Assessment Scale is a validated assessment tool used to describe the patient's level of distress relating to individual physical symptoms. The seven assessed items are insomnia, appetite problems, nausea, bowel problems, breathing problems, fatigue and pain. Symptoms are rated on a scale of 0 to 10, with '0' meaning no symptoms and '10' the worst symptoms imaginable 21 . Health service use was measured by patients keeping a diary of healthcare services used after discharge. Patients were phoned monthly to check which healthcare services were needed, provided and used.
The tools were administered by two research nurses at the time of hospital discharge (± seven days) by personal interview (in-hospital) and at six months (± 14 days) after hospital discharge by phone interview. Proxies were used for patients unable to complete their questionnaires 22, 23 and the responses treated the same as patient responses.
Data analysis
The primary outcomes were QOL and health service use. The secondary outcome was symptom profile. Cohort characteristics included age, sex, medical or surgical admission, diagnostic category (i.e. reason for admission to ICU), length-of-stay and ICU and hospital mortality. Data were described with mean or median for continuous data and frequencies for categorical data and compared between groups using intra-cluster correlation, as appropriate. Longitudinal random effects linear regression models using maximum likelihood estimation 24 were used to model SF-36v2 scores, EORTC QLQ-C15-PAL and the Symptom Assessment Scale. This method controls for the nested nature of the data with observations at different times clustered within patients clustered within matched groups. The robust method of estimation does not require the assumption of independent sampling which most statistical methods assume for the estimation of standard errors but there is a cost because the resulting estimates have greater standard errors and thus, are more conservative in estimating P-values. This will result in a reduction of statistical power for the study as a whole. The method allows for repeated observations over time and matching of patients. It also maximises power by including patients with missing observations. Independent variables entered into the model were cohort (severe comorbidity or no severe comorbidity) and followup time (hospital discharge or six months after hospital discharge). The interaction term for these two variables was also included in the models to test the hypothesis that change in the dependent variable over time was not different for the two groups. The matching of the patients between the severe comorbidity and no severe comorbidity groups also violated the assumption of independence that results in incorrect estimation of the standard errors and the P-values. Traditionally, this violation has been addressed by using conditional models for the analysis but this means that patients without a match were deleted from the analysis. As this would limit the already small sample size, we chose an alternative approach that used a robust method of estimation for standard errors by defining the data as clustered within ID and time. The need for care or support was also compared between cases and controls.
The sample size for this study is small and it is likely that it does not have sufficient power to detect relatively small differences between groups as statistically significant using the conventional P-value of less than 0.05 to indicate statistical significance. This problem is likely to be greatest for the group by time interaction effects, which normally require greater power than simple linear associations. We have reported the P-values but we urge readers to exercise caution when the values are greater than 0.05. This problem does not apply to P-values that are less than 0.05. Statistical analysis was conducted using IBM SPSS Statistics for Windows version 21.0 (IBM Corp, Armonk, NY, USA) and Stata version 12.0 (StataCorp, College Station, TX, USA).
Results
Sixty patients, 30 cases and 30 controls, were recruited over a 15-month period. Immunosuppression (from disease or treatment) was the most frequent severe comorbidity (14 patients), followed by 12 patients with cardiovascular diseases, seven with renal disease, five with respiratory disease and one patient with cirrhosis. Five of these patients had more than one severe comorbidity. No differences between the two groups were found in age (P=0.50), worst APACHE II score (P=0.24), proportion of males (P=0.75), length-of-stay in ICU (P=0.30) or length-of-stay in hospital (P=0.17). Four deaths occurred in the severe comorbidity group and one in the group without severe comorbidity in the six months after discharge from hospital. The majority of patients were discharged home. Cohort characteristics are shown in Table 1 .
QOL increased for both groups from hospital discharge to six months after hospital discharge. The mean physical component score was 29.6 for patients with severe comorbidity compared to 33.4 for patients without severe comorbidity. After adjusting for group, follow-up period and the interaction term, the increase to six months was significant but not the difference between groups (P=0.16). The Mental Component Summary of SF-36 also increased from hospital discharge to the six-month follow-up for both groups. The mean Mental Component Summary was 39.8 at hospital discharge compared to 41.5 at six months after hospital discharge but the increase to six months was not significant. However, the lower scores for patients with severe comorbidity was significant (P=0.005), as shown in Table 2 . Examining individual components ( Figure  1) , patients with severe comorbidity had lower mean scores compared to the patients with no severe comorbidity at hospital discharge. All components increased between hospital discharge and the six-month follow-up except for general health (P=0.03) and mental health (P=0.10) in the patients with no severe comorbidity in whom there was a slight decrease, as shown in Figure 1 . The differences between severe comorbidity and no severe comorbidity groups over time for general health (P <0.001), mental health (P=0.001) and vitality (P=0.035) were significant ( Table 2) . The global health status/QOL, estimated from the EORTC QLQ-C15-PAL scale, improved over the six-month followup (P <0.001) for both groups but not between groups. The changes for individual parameters were inconsistent ( Figure 2 ). Pain (P <0.001), dyspnoea (P <0.001), insomnia (P=0.002), appetite loss (P <0.001), constipation (P=0.12), fatigue (P <0.001) and nausea/vomiting (P <0.001) decreased significantly within groups but not between groups. Physical functioning (P=0.006) and emotional functioning (P=0.025) also increased significantly within groups. The results of the regression models are shown in Table 2 .
The seven primary symptoms of the Symptom Assessment Scale were reported but patients could also record other symptoms in addition to these. Other symptoms included confusion, anxiety, dizziness, dry mouth and dry skin. If there was more than one pain symptom (two patients), the maximum value is reported. There was a higher occurrence of symptoms in patients with severe comorbidity compared Table 2 Changes in quality of life after adjustment for group, follow-up time, 1) between comorbidity and no severe comorbidity groups, 2) from hospital discharge to six months after hospital discharge (within groups) and 3) interaction term (group*follow-up period) to patients without severe comorbidity, except for appetite, but the differences were not statistically significant ( Figure  3 ). The reduced symptom burden from hospital discharge to six months was significant for both patients with severe comorbidity and no severe comorbidity, although the improvement for the majority of symptoms was greater for patients with severe comorbidity. The most common symptom was fatigue in both the severe comorbidity and no severe comorbidity groups. Nineteen diaries were completed (30%) by ten patients with severe comorbidity and nine patients without severe comorbidity. Health services were grouped into: admitted to hospital (excluding day procedures), procedures (e.g. echocardiography, angiography), general practitioner consultations, specialist consultations, hospital clinics (advanced lung disease clinic, cardiac transplant service, other specialty clinics), physiotherapy, cardiac gym, dialysis, occupational therapy, home nursing services and other (blood tests and X-rays, unless during a clinic visit). The number of health services used by patients with severe comorbidity ranged from 0.4 to 4.5 per week and for patients with no severe comorbidity from 0.4 to 6.7 per week. No difference was found in the mean number of health services used per week between groups (2.0 versus 1.7, P=0.62). No patient reported using formal palliative care services in the ICU. One patient used hospice care after hospital discharge and certain disease groups received specialist care and follow-up such as the advanced lung disease clinic.
Discussion
We found an increase in QOL within, but not between, groups from hospital to six months after discharge. We are confident that it is valid to conclude that there was an improvement for both groups but we are unable to conclude that the change is not different between the groups because of limited study power. By helping patients and families clarify immediate and longer-term goals, clinicians can help them understand more clearly that intensive care ranges from aggressive intervention to palliative care 2 . It can also help them to better appreciate that different types or levels of care may be appropriate over the patient's intensive care course and post discharge. Initiating early discussion about patient preferences and palliative care needs promotes excellent palliative care simultaneously with curative and life-sustaining therapies in the ICU 2 . Lunney 25 describes the disease trajectory for people with severe, non-malignant comorbidity as being a slow downward progression with a series of exacerbations of the illness. It is possible that an ICU admission is useful to treat exacerbations and help patients to regain function.
Of concern is the possibility that treating exacerbations may lead to people living longer but with poor QOL. However, the results from this study do not suggest this. People with severe comorbidity, who were considered appropriate for ICU admission, showed significant improvements in mental health, vitality and social functioning and self-reported QOL, as well as decreased physical symptoms. This suggests that an ICU admission can enhance wellbeing of select people with severe comorbidity and is a viable option for people otherwise receiving palliative care.
Studies have shown that survivors of intensive care have a decreased rate of survival when compared to an age-, gender-and era-matched Australian population (that extends to at least 15 years 26 ), decreased QOL compared to that of the general population 27, 28 and often experience physical, psychological and cognitive impairment that may take months to years to recover 29, 30 . Survival is likely to be shorter among patients with severe comorbidity, therefore promoting symptom management and QOL is crucial. How the shortand long-term effects of ICU admission impact on outcomes for this group of patients is largely unknown. While it may often be assumed that patients with severe comorbidity who survive their admission to ICU have their healthcare needs met after their discharge from hospital, the truth of this assumption is unknown.
Limitations
This study failed to reach recruitment targets. We estimated that we could recruit 100 patients in a year but recruitment was much slower than we anticipated. Recruitment was discontinued after two years because of insufficient funding, resulting in a smaller sample than planned. Patients with severe comorbidity are a relatively small group of admissions to the ICU, suggesting a significant selection bias. We believed that the sample size of 50 patients in each group would provide important information on the wellbeing of critically ill patients after discharge from hospital. Nevertheless, the inability to find a difference between groups may be due to the small sample size.
We matched cases with controls but matching on age, sex and APACHE II score was difficult. While we took a liberal approach and often did not match based on sex, several patients did not have a control and several controls had no suitable cases, though this was adjusted for in the statistical analysis.
It is also likely that the patients admitted to the ICU with severe comorbidity had a reasonable prospect of survival and were likely to benefit from an ICU admission, i.e. the 'fitness effect'. While our ICU has no explicit selection criteria to exclude patients with severe comorbidity, it is likely that selection bias occurs. We recognise that the ICU is likely to admit only those patients who the admitting intensivist believes will benefit from ICU. As such, these results cannot be generalised to patients with severe comorbidity overall and are likely to apply to those in ICUs with admission patterns.
Conclusion
Patients with severe comorbidity had improved QOL and reduced symptom burden after an admission to ICU. Admitting these patients to ICU resulted in survival with improved QOL for individual patients.
